GleamWall
中文EN

AMLX Amylyx Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1658551 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-100.3%
TTM net income YoY42.5%
TTM EPS YoY53.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin100.0%
Operating margin23,660.3%
Net margin22,448.4%
FCF margin23,236.1%
EBITDA margin23,573.5%

Returns

ROE-56.5%
ROA-48.7%
ROIC (approx.)-107.5%
Asset turnover-0.00x

Leverage & solvency

Liabilities / assets8.5%
Debt / equity0.00x
Current ratio13.70x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.03x
Accruals ratio1.7%
Payout ratio—
Capex / revenue-10.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$87.37M
Cost of revenue$0$5.95M
Gross profit$0$81.42M
R&D expense$90.40M$104.08M
SG&A expense$62.89M$114.33M
Operating income-$153.29M-$314.73M
Pretax income-$144.69M-$302.14M
Income tax$46,000-$393,000
Net income-$144.74M-$301.74M
EBITDA-$152.77M-$313.83M
EPS (basic)-1.53-4.43
EPS (diluted)-1.53-4.43
Weighted avg. shares (diluted)94.57M68.14M
Balance sheet
Cash & equivalents$226.65M$77.39M
Short-term investments$90.33M$99.11M
Receivables$88,000$447,000
Current assets$323.67M$189.43M
PP&E, net$310,000$961,000
Total assets$332.64M$193.63M
Current liabilities$22.69M$28.41M
Total liabilities$27.39M$28.87M
Shareholders' equity$305.26M$164.76M
Shares outstanding109.88M68.63M
Cash flow statement
Operating cash flow-$123.34M-$167.65M
Capital expenditure$138,000$157,000
Free cash flow-$123.48M-$167.80M
Investing cash flow$14.04M$75.65M
Financing cash flow$257.03M$348,000
Depreciation & amortization$525,000$904,000
Stock-based compensation$27.64M$33.04M

Free plan shows the latest 2 periods; Pro shows all 5 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.